Researchers at Nventa are striving to discover new therapeutic options to satisfy serious diseases with unmet medical needs to improve patients' lives.  The Company’s main area of research is on further applications of its fusion technology to create other CoVal™ fusion proteins.

Nventa has been investigating other fusion proteins that, like HspE7, are made using its proprietary technology. These are based on covalently bonding a heat shock protein (Hsp) to an antigen expressed by a virus or cancer. The Company will need substantial additional resources, either through additional financings or collaborations with pharmaceutical partners, to further the development of these follow-on products.